鎌状赤血球貧血検査・スクリーニング市場：技術別、年齢層別、セクター別-2024～2030年の世界予測

鎌状赤血球貧血検査・スクリーニング市場規模は2023年に9億4,395万米ドルと推定され、2024年には10億7,069万米ドルに達し、CAGR 13.51％で2030年には22億9,322万米ドルに達すると予測されます。

鎌状赤血球症（SCD）として知られる鎌状赤血球貧血は、全身の細胞に酸素を供給する赤血球中の分子であるヘモグロビンに影響を及ぼす遺伝子疾患です。鎌状赤血球貧血の人はヘモグロビンSを持っており、赤血球を鎌状（三日月状）にゆがめることがあります。この鎌状赤血球は、血管内を流れにくく、体の各部への血流を阻害するため、慢性疼痛、重篤な感染症、その他の合併症を引き起こす可能性があります。世界中で鎌状赤血球貧血の有病率が増加しており、検査・スクリーニング・ソリューションの採用を促進しています。加えて、新興国におけるヘルスケア・インフラの拡大が、検査・スクリーニング・サービスへのアクセス拡大と普及を後押ししています。しかし、遺伝子検査にかかる費用が高く、償還政策が限られているため、特に低所得国では市場の成長を阻害する可能性があります。さらに、分子診断学とハイスループットスクリーニング法の革新は、検査プロセスを合理化し、精度を高め、所要時間を短縮しています。

技術特に新生児の初期スクリーニングのためのヘモグロビン電気泳動の継続的進歩

ヘモグロビン電気泳動は、電荷とサイズに基づいて異なるタイプのヘモグロビンを識別するために広く使用されている伝統的な検査技術です。この検査は、鎌状赤血球貧血などの疾患を示す異常ヘモグロビンを検出することを目的としています。確定診断が必要な場合に好まれます。等電点電気泳動（IEF）は、ヘモグロビンの異型を等電点（pI）、すなわち分子が正味の電荷を持たないpHで分離する特殊な電気泳動法です。IEFは、酢酸セルロースまたはキャピラリー電気泳動による最初のスクリーニングの後、確認検査としてしばしば使用されます。高速液体クロマトグラフィー（HPLC）は、様々なヘモグロビンの定量および同定に用いられる強力な分析技術です。HPLCは、その精度と迅速な納期により、鎌状赤血球症のスクリーニングに頻繁に使用されています。鎌状赤血球貧血のPOCT（Point-of-Care Test）検査は、患者の診療時点またはその近くで使用するために設計された診断ツールです。POCTは、その利便性、迅速性、そして資源の限られた国々を含む様々な環境において早期かつ容易な検出を可能にする能力から高く評価されています。ラテラル・フロー・イムノアッセイ（LFIA）は、生体試料中のタンパク質、病原体、分子マーカーなどの特定分析物の存在を検出するために発明された、シンプルで携帯可能な装置です。LFIAはテストストリップの形式を利用し、血液サンプル中の鎌状赤血球ヘモグロビンの有無を視覚的に表示します。紙ベースの迅速診断薬は、紙の吸収性を利用したPOC検査の革新的なアプローチです。費用対効果が高く、ユーザーフレンドリーなこの検査は、必要な検体量も最小限に抑えられ、高度な検査インフラが整っていない地域でも巧みに利用することができます。

セクター企業ラボは、包括的なサービスを提供するために、技術革新とテクノロジーの最前線にいます。

企業ラボは、鎌状赤血球貧血の検出に使用されるものを含め、診断検査の開発と提供において重要な役割を果たすことが多いです。このような研究所は通常、高スループットの検査能力を提供し、充実した研究開発資源を有しています。最新かつ最も包括的な検査オプションを求める患者やヘルスケアプロバイダーに好まれています。政府系研究所は通常、国または地方政府の保健部門によって資金提供され、運営されています。これらの研究所は、鎌状赤血球貧血の新生児スクリーニング・プログラムなど、公衆衛生のサーベイランスや疾病予防の取り組みにとって極めて重要です。特にリスクの高い地域社会を対象として、住民に利用しやすい補助金付きのサービスを提供することに重点を置いています。民間の検査施設は、個別化された検査サービスを提供し、多くの場合、プライバシーと迅速な結果を求める顧客に対応しています。このような検査施設は、地元の小規模施設から大規模な高級施設まで様々です。顧客が好むのは、顧客サービスの質、迅速な納期、自己負担または民間保険による支払い能力です。官民パートナーシップは、民間セクターの効率性と公共セクターのアクセシビリティを活用し、ヘルスケアサービスを向上させるコラボレーションです。このようなパートナーシップは、資源が限られ、鎌状赤血球貧血の負担が大きい地域では特に効果的です。PPPは、検診プログラムの拡大やケアネットワークの統合に役立ちます。

地域的洞察

アメリカ地域では、定期的なスクリーニングだけでなく、正確で早期診断に対する消費者のニーズが高いです。これは、確立された新生児スクリーニング・プログラムや、CDCによる鎌状赤血球症新生児スクリーニング・プログラムなどの取り組みに反映されています。これらの地域における顧客の購買行動は、ヘルスケア保険政策と遺伝子検査の適用範囲に影響を受けています。鎌状赤血球貧血に対する認識とスクリーニングは、EU諸国によって異なります。鎌状赤血球貧血がより流行している欧州地域の国々では、より強固なスクリーニングプログラムが実施されています。欧州血液学会は、調査に積極的に取り組んでいる団体のひとつです。EUの消費者のSCA検査に対する購買行動は、ヘルスケア規制と国の医療サービスの利用可能性によって動機づけられています。アフリカにおける鎌状赤血球貧血検査およびスクリーニング市場は、この疾患の高い有病率のために重要です。手頃な価格で利用可能なSCA検査オプションに対する需要が高まっています。鎌状赤血球貧血は、公衆衛生上の懸念が残るインドに対応して、日本や中国などの東アジア諸国でわずかに流行しています。インドでは、SCAスクリーニングは、特に部族地域において、より広範な保健活動に組み込まれています。アジア太平洋地域の消費者ニーズは様々であるが、遺伝性疾患や早期検査の利点に対する認識は高まっています。

FPNVポジショニング・マトリックス

FPNVポジショニング・マトリックスは鎌状赤血球貧血検査・スクリーニング市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、鎌状赤血球貧血検査・スクリーニング市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.鎌状赤血球貧血検査・スクリーニング市場の市場規模および予測は？

2.鎌状赤血球貧血検査・スクリーニング市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.鎌状赤血球貧血検査・スクリーニング市場の技術動向と規制枠組みは？

4.鎌状赤血球貧血検査・スクリーニング市場における主要ベンダーの市場シェアは？

5.鎌状赤血球貧血検査・スクリーニング市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 鎌状赤血球症の世界の蔓延
    • 診断を支援するための政府の継続的な取り組み
    • 鎌状赤血球症に対する高速液体クロマトグラフィー（HPLC）検査の重要な利用
  • 抑制要因
    • 鎌状赤血球貧血症に関連する診断と治療の問題
  • 機会
    • 鎌状赤血球貧血の自動スクリーニングを実行するために設計されたディープラーニングフレームワークの開発
    • 非侵襲性、携帯性、デジタル技術の開発への注目が高まる
  • 課題
    • SCDに関連する臨床的異質性と合併症
    • リソース不足と熟練した臨床検査技師の不足
• 市場セグメンテーション分析
  • 技術：特に新生児の初期スクリーニングのためのヘモグロビン電気泳動の継続的な進歩
  • セクター：企業ラボは、包括的なサービスを提供するために革新と技術の最前線に立っています。
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 鎌状赤血球貧血検査・スクリーニング市場：技術別

• ヘモグロビン電気泳動
• 高速液体クロマトグラフィー（HPLC）
• ポイントオブケア検査

第7章 鎌状赤血球貧血検査・スクリーニング市場：年齢層別

• 成人スクリーニング
• 新生児スクリーニング
• 1年目から25年目

第8章 鎌状赤血球貧血検査・スクリーニング市場セクター別

• コーポレートラボ
• 政府研究所
• プライベートラボ
• 官民パートナーシップ

第9章 南北アメリカの鎌状赤血球貧血検査・スクリーニング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の鎌状赤血球貧血検査・スクリーニング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの鎌状赤血球貧血検査・スクリーニング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • 血圧薬のSCDへの転用研究に300万米ドルが授与される
  • Mylabが独自のポイントオブケア型迅速鎌状赤血球貧血検査を導入
  • ロードズ・マーク・インダストリーズとインド工科大学ボンベイ校が提携し、インドで鎌状赤血球検査を推進

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET RESEARCH PROCESS
• FIGURE 2. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. SICKLE CELL ANEMIA TESTING & SCREENING MARKET DYNAMICS
• FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ISOELECTRIC FOCUSING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ISOELECTRIC FOCUSING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PAPER BASED RAPID DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PAPER BASED RAPID DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULT SCREENING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULT SCREENING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY YEARS 1 TO 25, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY YEARS 1 TO 25, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CORPORATE LABS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CORPORATE LABS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC-PRIVATE-PARTNERSHIPS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC-PRIVATE-PARTNERSHIPS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 47. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 48. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 49. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 50. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 51. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 52. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 53. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 54. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 55. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 56. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 57. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 58. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 59. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 60. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 61. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 62. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 63. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 64. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 65. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 66. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 67. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 68. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 69. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 70. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 71. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 72. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 73. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 74. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 75. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 76. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 77. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 78. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 79. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 80. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 81. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 82. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 83. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 84. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 85. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 86. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 87. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 88. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 89. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 90. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 91. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 92. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 93. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 94. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 95. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 96. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 97. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 98. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 99. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 100. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 101. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 102. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 103. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 104. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 105. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 106. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 108. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 110. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 112. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 114. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 116. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 118. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 119. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 120. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 121. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 122. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 123. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 124. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 125. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 126. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 127. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 128. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 129. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 130. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 131. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 132. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 133. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 134. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 135. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 136. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 137. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 138. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 139. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 140. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 141. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 142. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 143. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 144. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 145. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 146. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 147. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 148. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 149. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 150. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 151. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 152. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 153. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 154. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 155. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 156. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 157. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 158. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 159. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 160. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 161. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 162. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 163. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 164. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 165. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 166. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 167. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 168. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 169. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 170. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 171. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 172. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 173. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 174. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 175. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 176. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 177. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 178. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 179. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 180. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 181. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 182. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 183. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 184. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 185. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 186. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 187. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 188. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 189. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 190. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 191. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 192. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 193. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 194. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 195. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 196. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 197. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 198. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 200. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 202. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 204. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 206. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 208. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 209. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 210. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 211. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 212. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 213. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 214. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 215. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 216. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 217. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 218. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 219. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 220. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 221. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 222. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 223. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 224. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 225. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 226. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 227. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 228. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 229. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 230. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 231. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 232. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 233. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 234. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 235. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 236. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 237. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 238. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 251. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 252. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 253. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 254. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 255. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 256. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 257. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 258. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 259. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 260. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 261. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 262. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 263. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 264. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 265. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 266. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 267. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 268. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 269. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 270. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 271. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 272. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 273. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2023 (USD MILLION)
• TABLE 274. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2024-2030 (USD MILLION)
• TABLE 275. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2023 (USD MILLION)
• TABLE 276. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2024-2030 (USD MILLION)
• TABLE 277. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 278. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 279. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2023 (USD MILLION)
• TABLE 280. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2024-2030 (USD MILLION)
• TABLE 281. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 282. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 283. FRANCE SICKLE CELL ANEMIA TESTING & SC

[185 Pages Report] The Sickle Cell Anemia Testing & Screening Market size was estimated at USD 943.95 million in 2023 and expected to reach USD 1,070.69 million in 2024, at a CAGR 13.51% to reach USD 2,293.22 million by 2030.

Sickle cell anemia, known as sickle cell disease (SCD), is a genetic disorder that affects hemoglobin, the molecule in RBCs that delivers oxygen to cells throughout the body. People with sickle cell anemia have hemoglobin S, which can warp red blood cells into a sickle, or crescent, shape. These sickled cells can cause chronic pain, serious infections, and other complications because they do not flow through blood vessels easily and can block blood flow to parts of the body. Increasing prevalence of sickle cell anemia across the globe driving the adoption of testing & screening solutions. In addition, expanding healthcare infrastructure in emerging economies supports greater access to and adoption of testing and screening services. However, the high cost of genetic testing and limited reimbursement policies can impede market growth, particularly in low-income countries. Furthermore, innovations in molecular diagnostics and high-throughput screening methods are streamlining the testing process, increasing its accuracy, and reducing turnaround times.

Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns

Hemoglobin electrophoresis is a traditional testing technique widely used to identify different types of hemoglobin based on their electrical charge and size. This test aims to detect abnormal hemoglobin, which can indicate disorders, including sickle cell anemia. It's preferred in cases where definitive diagnosis is required. Isoelectric focusing (IEF) is a specialized form of electrophoresis that separates hemoglobin variants by their isoelectric point (pI), the pH at which a molecule carries no net charge. IEF is often used as a confirmatory test following initial screening with cellulose acetate or capillary electrophoresis. High-performance Liquid Chromatography (HPLC) is a powerful analytical technique employed for the quantification and identification of various hemoglobins. HPLC is frequently used for sickle cell disease screening due to its accuracy and rapid turnaround time. Point-of-care tests (POCT) for sickle cell anemia are diagnostic tools designed for use at or near the point of patient care. They are prized for their convenience, speed, and the ability to enable early and easy detection in a variety of settings, including countries with limited resources. Lateral flow immunoassays (LFIA) are simple, portable devices invented to detect the presence of specific analytes such as proteins, pathogens, and molecular markers in a biological sample. Utilizing a test strip format, LFIAs create a visual representation of the presence and absence of sickle cell hemoglobin in a blood sample. Paper-based rapid diagnostics are an innovative approach to POC testing that leverages the absorbent nature of paper to conduct assays. These cost-effective and user-friendly tests require minimal sample volume and can be adeptly employed in areas lacking advanced laboratory infrastructure.

Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services

Corporate labs often play a significant role in the development and provision of diagnostic tests, including those used for the detection of sickle cell anemia. These labs typically offer high-throughput testing capabilities and have substantial research and development resources. They are preferred by patients and healthcare providers who are seeking the latest and most comprehensive testing options. Government labs are usually funded and operated by national or regional government health departments. These labs are crucial for public health surveillance and disease prevention efforts, including newborn screening programs for sickle cell anemia. They focus on providing accessible and subsidized services to the population, particularly targeting high-risk communities. Private labs provide personalized testing services and often cater to a clientele seeking privacy and expedited results. These labs can range from small-scale local facilities to large, high-end operations. Their preference is based on the quality of customer service, faster turnaround times, and the ability to pay out-of-pocket or through private insurance. Public-private partnerships are collaborations that leverage the efficiency of the private sector and the accessibility of the public sector to enhance healthcare services. These partnerships can be particularly effective in regions where resources are limited and the burden of sickle cell anemia is high. PPPs can serve to expand screening programs and integrate care networks.

Regional Insights

In the American region, there is a high consumer need for accurate and early diagnosis, as well as routine screening. This is reflected in established newborn screening programs and initiatives such as the Sickle Cell Disease Newborn Screening Program by the CDC. Customer purchasing behavior in these regions is influenced by healthcare insurance policies and coverage for genetic testing. The awareness and screening for sickle cell anemia vary across EU countries. Countries in the European region, where the disease is more prevalent, have more robust screening programs. The European Hematology Association is one organization actively engaging in research. The EU consumer purchasing behavior for SCA testing is motivated by healthcare regulations and the availability of national health services. The sickle cell anemia testing and screening market in Africa is significant due to the high prevalence of the disease. There is a growing demand for affordable and available testing options for SCA. Sickle cell anemia is slightly prevalent in East Asian countries such as Japan and China, corresponding to India, where it remains a public health concern. In India, SCA screening is incorporated into broader health initiatives, particularly in tribal regions. Consumer needs in the Asia Pacific region vary, but there is increasing awareness about genetic diseases and the benefits of early testing.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sickle Cell Anemia Testing & Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sickle Cell Anemia Testing & Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sickle Cell Anemia Testing & Screening Market, highlighting leading vendors and their innovative profiles. These include Agios Pharmaceuticals, Inc., Anamol Laboratories Pvt. Ltd., Atlas Medical GmbH, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Biomedomics Inc., Bluebird bio, Inc., Calibre Scientific, Inc., CRISPR Therapeutics AG, Edvotek Inc., Hemex Health, HiMedia Laboratories, Laboratory Corporation of America Holdings, Maternova Inc., PerkinElmer, Inc., Pfizer Inc., PicnicHealth, Quest Diagnostics Incorporated, Silver Lake Research Corporation, Streck, Inc., Thermo Fisher Scientific Inc., Ulta Lab Tests, LLC, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Hemoglobin Electrophoresis
    • Isoelectric focusing

• High-performance Liquid Chromatography (HPLC)
• Point-of-Care Tests
  • Lateral Flow Immunoassay
  • Paper Based Rapid Diagnostics
• Age Group
  • Adult Screening
  • Newborn Screening
  • Years 1 to 25

• Sector
  • Corporate Labs
  • Government Labs
  • Private Labs
  • Public-Private-Partnerships

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Sickle Cell Anemia Testing & Screening Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sickle Cell Anemia Testing & Screening Market?

3. What are the technology trends and regulatory frameworks in the Sickle Cell Anemia Testing & Screening Market?

4. What is the market share of the leading vendors in the Sickle Cell Anemia Testing & Screening Market?

5. Which modes and strategic moves are suitable for entering the Sickle Cell Anemia Testing & Screening Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of Sickle Cell Disease Worldwide
    • 5.1.1.2. Ongoing Government Initiatives to Support the Diagnosis
    • 5.1.1.3. Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
  • 5.1.2. Restraints
    • 5.1.2.1. Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
    • 5.1.3.2. Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Clinical Heterogeneity and Complications Associated with SCD
    • 5.1.4.2. Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns
  • 5.2.2. Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Sickle Cell Anemia Testing & Screening Market, by Technology

• 6.1. Introduction
• 6.2. Hemoglobin Electrophoresis
• 6.3. High-performance Liquid Chromatography (HPLC)
• 6.4. Point-of-Care Tests

7. Sickle Cell Anemia Testing & Screening Market, by Age Group

• 7.1. Introduction
• 7.2. Adult Screening
• 7.3. Newborn Screening
• 7.4. Years 1 to 25

8. Sickle Cell Anemia Testing & Screening Market, by Sector

• 8.1. Introduction
• 8.2. Corporate Labs
• 8.3. Government Labs
• 8.4. Private Labs
• 8.5. Public-Private-Partnerships

9. Americas Sickle Cell Anemia Testing & Screening Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. USD 3 million awarded to study repurposing of blood pressure drug for SCD
  • 12.3.2. Mylab introduces indigenous Point-of-care, Rapid Sickle Cell Anemia Test
  • 12.3.3. Lord's Mark Industries, IIT-Bombay partner to advance sickle cell testing in India

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio